QSAM Biosciences, Inc. (QSAM)
| Previous close | 16,600.00 |
| Open | 7.75 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 7.74 - 8.30 |
| 52-week range | 4.10 - 16,600.00 |
| Volume | |
| Avg. volume | 6,095 |
| Market cap | 36.897M |
| Beta (5Y monthly) | 1.81 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.69 |
| Earnings date | 13 May 2024 - 18 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireQSAM ANNOUNCES REVERSE STOCK SPLIT RATIO AHEAD OF MERGER
Austin, TX, April 16, 2024 (GLOBE NEWSWIRE) -- QSAM Biosciences, Inc. (OTCQB: QSAM) (“QSAM” or the “Company”) previously announced that it will effectuate a reverse stock split of the issued and outstanding shares of QSAM’s common stock, par value $0.0001 per share (“Common Stock”), at a ratio in the range of 1:1000 to 1:2000, prior to the closing of the merger between the Company and Telix Pharmaceuticals Limited (ASX: TLX) (“Telix”) pursuant to which Telix will acquire QSAM (the “Merger”). On
- GlobeNewswire
QSAM Biosciences Signs Definitive Agreement to be Acquired by Telix Pharmaceuticals
Austin, TX, Feb. 07, 2024 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM) (“QSAM or the “Company”) has signed a definitive Agreement and Plan of Merger (the “Agreement”) providing for the acquisition of the Company by Telix Pharmaceuticals Limited (ASX: TLX) (“Telix”). Pursuant to the Agreement, QSAM stockholders will receive (i) $33.1 million in Telix ordinary shares (“Telix Shares”) or cash, less an adjustment amount equal to QSAM’s indebtedness and payables as of the merger closing (t
- GlobeNewswire
QSAM Biosciences Signs Term Sheet to be Acquired by Telix Pharmaceuticals; Receives $2 Million Pre-Closing Collaboration and Option Fee
Austin, TX, Nov. 14, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing therapeutic radiopharmaceuticals for the treatment of primary and secondary bone cancer and related conditions, has signed a non-binding term sheet (the “Term Sheet”) with Telix Pharmaceuticals (US) Inc., a subsidiary of Telix Pharmaceuticals Limited (ASX: TLX) (collectively, “Telix”) providing material terms for the acquisition of the Company by Telix by means of a merger (the “Acquisition”).
